cytomx
therapeutics
announces
new
employment
inducement
grants
south
san
francisco
globe
newswire
cytomx
therapeutics
nasdaq
ctmx
biopharmaceutical
company
pioneering
novel
class
investigational
antibody
therapeutics
based
technology
platform
today
announced
september
company
granted
nine
new
employees
options
purchase
total
shares
company
common
stock
exercise
price
per
share
equal
closing
trading
price
september
date
grant
stock
options
granted
pursuant
company
employment
inducement
incentive
plan
approved
company
board
directors
august
rule
c
nasdaq
global
market
equity
grants
induce
new
employees
enter
employment
company
cytomx
therapeutics
cytomx
biopharmaceutical
company
vision
transforming
lives
safer
effective
therapies
developing
novel
class
investigational
antibody
therapeutics
based
technology
platform
treatment
cancer
cytomx
strategic
drug
discovery
development
collaborations
abbvie
amgen
astellas
bristol
myers
squibb
probody
therapeutics
designed
remain
inactive
activated
proteases
tumor
microenvironment
result
probody
therapeutics
intended
bind
selectively
tumors
decrease
binding
healthy
tissue
minimize
toxicity
potentially
create
safer
effective
therapies
leaders
field
innovative
technology
designed
turn
previously
undruggable
targets
druggable
targets
enable
effective
combination
therapies
cytomx
partners
comprised
leading
biotechnology
pharmaceutical
companies
developed
robust
pipeline
potential
therapeutic
candidates
novel
difficult
drug
targets
potential
immunotherapeutic
candidates
clinically
validated
targets
cytomx
clinical
stage
pipeline
includes
product
candidates
previously
undruggable
targets
including
probody
drug
conjugate
wholly
owned
cytomx
probody
drug
conjugate
partnered
abbvie
among
cancer
targets
considered
inaccessible
conventional
antibody
drug
conjugates
due
presence
many
healthy
tissues
cytomx
clinical
stage
pipeline
also
includes
cancer
immunotherapeutic
candidates
validated
targets
wholly
owned
probody
therapeutic
probody
therapeutics
partnered
bristol
myers
squibb
additional
information
cytomx
therapeutics
visit
follow
us
linkedin
twitter
probody
registered
trademark
cytomx
therapeutics
contact
investors
media
